PUR Biologics Expands Sales Network by 15%, Adding 32 New Distributors
HippoFi, Inc. (OTC PINK: ORHB) announced a significant expansion of its biologics division, PUR Biologics, by adding 32 new distributors to its network. This growth reflects the increasing demand for PUR Biologics' high-quality products in the ortho-spine market, increasing the total number of distributors to 239. The company's leadership anticipates that this expansion will positively impact product sales in the second half of 2023. PUR Biologics specializes in biologic solutions for critical health issues, aiming to improve patient outcomes through innovative products. With a strong focus on quality and technology, PUR Biologics is well-positioned to lead in the biologics industry.
- Expansion with 32 new distributors increases PUR Biologics' total to 239.
- Expected positive impact on product sales in the second half of 2023.
- Strong partnerships and sales channels enhance market presence.
- None.
IRVINE, CA / ACCESSWIRE / April 27, 2023 / HippoFi, Inc. (OTC PINK:ORHB), a leading healthcare innovator and technology company, is proud to announce the expansion of its biologics division, PUR Biologics. The addition of 32 new distributors to PUR Biologics' distribution network is a testament to the growing demand for its high-quality products and expertise in ortho-spine biologics. With these new distributors, PUR Biologics has significantly increased its reach and access to new customers, bringing its total number of distributors specializing in the surgical spine and orthopedic market to 239.
"We're excited to see PUR Biologics' continued growth and expansion," said HippoFi Founder, Executive Chairman & CEO, CJ Wiggins. "Our team's dedication and hard work is reflected in the addition of these new distributors."
PUR Biologics specializes in the development and sales of biologics that offer effective solutions to critical health problems. The company's management believes that the new distributors will have a positive impact on product sales as early as the second half of 2023, bringing valuable experience and expertise to the company.
"We're thrilled to partner with PUR Biologics and bring their innovative products to our customers," said Brooks Kieschnick, President of Dispersion Group. "Their commitment to quality and innovation aligns with our own values, and we look forward to working together to improve patient outcomes and advance the field of biologics."
PUR Biologics' success is due in part to its strong partnerships with leading product development organizations and broad sales channels, as well as its commitment to advancing technology and quality. "With the continued growth of our distribution network, industry-leading product pipeline, and breakthrough technologies, PUR Biologics is well-positioned to continue to lead this space and drive further growth in the biologics industry," said Ryan Fernan, Head of PUR Biologics.
HippoFi, Inc. is publicly traded under the symbol: ORHB and is headquartered in Irvine, California. For more information, please visit: www.HippoFi.com and www.PURbiologics.com.
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare innovations through an extensive sales channel network while implementing first-to-market solutions in the multibillion-dollar Biotech, Fintech, and Artificial Intelligence (AI) markets. HippoFi comprises three segments: Regenerative Therapeutics, Digital Payments, and AI, which utilize the same customer channels to commercialize solutions, drive revenue, and improve patient outcomes.
About PUR Biologics
PUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTC PINK: ORHB), is a leading biologic company committed to supporting surgeons and hospitals in providing the best care for their patients. PUR Biologics' full line of biologic products currently include: advanced allografts and demineralized extracellular matrixes (d-ECM), innovative synthetic solutions, cellular derived tissues, and a future of next generation regenerative stem cell and growth factor driven therapeutics for treating osteoarthritis and cartilage regeneration.
Contact:
Jason Brown
Shareholder Communications HippoFi, Inc.
612-209-7565
SOURCE: ORHUB, Inc.
View source version on accesswire.com:
https://www.accesswire.com/751574/PUR-Biologics-Expands-Sales-Network-by-15-Adding-32-New-Distributors
FAQ
What recent development has HippoFi, Inc. (ORHB) announced regarding PUR Biologics?
How will the new distributors affect PUR Biologics' sales?
What market does PUR Biologics focus on?
What is the total number of distributors for PUR Biologics after the recent addition?
What does PUR Biologics specialize in?
